Epigenetics Drugs and Diagnostic Technologies Market Research Report Forecast to 2032

List of Tables

Market Overview

The Epigenetics Drugs and Diagnostic Technologies Market is anticipated to register a substantial CAGR of 21.90% during the review period.

The development of the market is driven by elements like the rising pervasiveness of persistent diseases like Focal Sensory system (CNS) diseases and oncology and the rising number of product dispatches and pipeline products.

The rising incidences of ongoing diseases of the focal sensory system across the globe are expanding the demand for epigenetic drugs and diagnostic technologies. Epigenetics significantly treat focal sensory system diseases, including Alzheimer's, Huntington's disease, schizophrenia, chemical imbalance, and bipolar disorder. Moreover, these drugs have low poisonousness and can be given in mix with different kinds of drugs for better treatment.

Additionally, epigenetics has shown extraordinary outcomes in treating malignant growth, and these drugs could switch off Deoxyribonucleic Acid (DNA). According to GLOBOCAN 2020, bosom disease accounted for the biggest offer, followed by lung, colorectum, prostate, stomach, and different malignant growths.

Market Segmentation

The market segments of epigenetics drugs and diagnostic technologies, based on drug type, into DNA methyltransferases (DNMTs) inhibitors, histone deacetylases (HDACs) inhibitors, histone methyltransferase (HMT) inhibitors, and others including bromodomain inhibitors, protein methyltransferase inhibitors, and histone acetyltransferases (HAT) inhibitors. The DNA methyltransferases (DNMTs) inhibitors segment is further segmented into azacitidine, decitabine, and others including zebularine, hydralazine, and procaine, and histone deacetylases (HDACs) inhibitors are further segmented into vorinostat, romidepsin, and others including belinostat, panobinostat, and trichostatin A.

The diagnostic technologies segment is classified into DNA methylation and histone modification analysis and others, including non-coding RNA analysis and epigenomic profiling.

Based on application, the market is separated into oncology, neurology, autoimmune diseases, and others. Based on end users the market is segmented into hospitals & and clinics, diagnostic centers, and others, including academic and research institutes and ambulatory surgical centers.

Regional Insights

North America epigenetics drugs and diagnostic technologies market held the biggest market share in 2022, due to the rising incidences of ongoing diseases and the presence of major and dynamic players including Illumina, Inc. (US), Gilead Sciences, Inc. (US), Celleron Therapeutics (US), LISEN lmprinting Diagnostics (US), and Salarius Drugs, Inc. (US).

Europe's epigenetics drugs and diagnostic technologies market accounted for the second-biggest market share due to the rising predominance of hereditary disorders and the send-off of epigenetic tests to detect hereditary disorders.

The Asia-Pacific epigenetics drugs and diagnostic technologies market is anticipated to register a healthy market growth owing to the developing incidence of neurological diseases and expanding coordinated efforts for the development of the drugs. According to the Alzheimer's Disease Global revealed in 2020, there are higher possibilities of Alzheimer's in developing nations including China, India, South Asia, and Western Pacific neighbors due to the quick development of the geriatric populace.

Major Players

Key Companies in the market of Epigenetics Drugs and Diagnostic Technologies are Hologic, Inc. (US), Gilead Sciences, Inc. (US), Celleron Therapeutics (US), Illumina, Inc. (US), AstraZeneca PLC (UK), LISEN lmprinting Diagnostics (US), Salarius Pharmaceuticals, Inc. (US), Jubilant Therapeutics (US), Oryzon Genomics (Spain), and Epiaxis Therapeutics (Australia).

Product Code: MRFR/HC/10457-CR

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET INTRODUCTION

2.1. DEFINITION
2.2. SCOPE OF THE STUDY
- 2.2.1. RESEARCH OBJECTIVE
- 2.2.2. ASSUMPTIONS
- 2.2.3. LIMITATIONS

3. RESEARCH METHODOLOGY

3.1. OVERVIEW
3.2. DATA MINING
3.3. SECONDARY RESEARCH
3.4. PRIMARY RESEARCH
- 3.4.1. PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
- 3.4.2. BREAKDOWN OF PRIMARY RESPONDENTS
3.5. FORECASTING TECHNIQUE
3.6. MARKET SIZE ESTIMATION
- 3.6.1. BOTTOM-UP APPROACH
- 3.6.2. TOP-DOWN APPROACH
3.7. DATA TRIANGULATION
3.8. VALIDATION

4. MARKET DYNAMICS

4.1. OVERVIEW
4.2. DRIVERS
4.3. RESTRAINTS
4.4. OPPORTUNITIES

5. MARKET FACTOR ANALYSIS

5.1. VALUE CHAIN ANALYSIS
5.2. PORTER'S FIVE FORCES ANALYSIS
- 5.2.1. BARGAINING POWER OF SUPPLIERS
- 5.2.2. BARGAINING POWER OF BUYERS
- 5.2.3. THREAT OF NEW ENTRANTS
- 5.2.4. THREAT OF SUBSTITUTES
- 5.2.5. INTENSITY OF RIVALRY
5.3. COVID-19 IMPACT ANALYSIS
- 5.3.1. MARKET IMPACT ANALYSIS
- 5.3.2. REGIONAL IMPACT
- 5.3.3. OPPORTUNITY AND THREAT ANALYSIS

6. GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE

6.1. OVERVIEW
6.2. DNA METHYLTRANSFERASES (DNMTS) INHIBITORS
- 6.2.1. AZACITIDINE
- 6.2.2. DECITABINE
- 6.2.3. OTHERS
6.3. HISTONE DEACETYLASES (HDACS) INHIBITORS
- 6.3.1. VORINOSTAT
- 6.3.2. ROMIDEPSIN
- 6.3.3. OTHERS
6.4. HISTONE METHYLTRANSFERASE (HMT) INHIBITORS
6.5. OTHERS

7. GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES

7.1. OVERVIEW
7.2. DNA METHYLATION
7.3. HISTONE MODIFICATION ANALYSIS
7.4. OTHERS

8. GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION

8.1. OVERVIEW
8.2. ONCOLOGY
8.3. NEUROLOGY
8.4. AUTOIMMUNE DISEASES
8.5. OTHERS

9. GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER

9.1. OVERVIEW
9.2. HOSPITALS & CLINICS
9.3. DIAGNOSTIC LABORATORIES
9.4. OTHERS

10. GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY REGION

10.1. OVERVIEW
10.1. NORTH AMERICA
- 10.1.1. US
- 10.1.2. CANADA
10.2. EUROPE
- 10.2.1. GERMANY
- 10.2.2. FRANCE
- 10.2.3. UK
- 10.2.4. ITALY
- 10.2.5. SPAIN
- 10.2.6. REST OF EUROPE
10.3. ASIA-PACIFIC
- 10.3.1. CHINA
- 10.3.2. INDIA
- 10.3.3. JAPAN
- 10.3.4. SOUTH KOREA
- 10.3.5. AUSTRALIA
- 10.3.6. REST OF ASIA-PACIFIC
10.4. REST OF THE WORLD
- 10.4.1. MIDDLE EAST
- 10.4.2. AFRICA
- 10.4.3. LATIN AMERICA

11. COMPANY LANDSCAPE

11.1. OVERVIEW
11.2. COMPETITIVE ANALYSIS
11.3. MARKET SHARE ANALYSIS
11.4. MAJOR GROWTH STRATEGY IN THE GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET
11.5. COMPETITIVE BENCHMARKING
11.6. LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET
11.7. KEY DEVELOPMENTS AND GROWTH STRATEGIES
- 11.7.1. NEW PRODUCT LAUNCH
- 11.7.2. MERGER & ACQUISITIONS
- 11.7.3. JOINT VENTURES
11.8. MAJOR PLAYERS FINANCIAL MATRIX
- 11.8.1. SALES & OPERATING INCOME, 2022
- 11.8.2. MAJOR PLAYERS R&D EXPENDITURE. 2022

12. COMPANY PROFILES

12.1. HOLOGIC, INC.
- 12.1.1. COMPANY OVERVIEW
- 12.1.2. FINANCIAL OVERVIEW
- 12.1.3. PRODUCTS OFFERED
- 12.1.4. KEY DEVELOPMENTS
- 12.1.5. SWOT ANALYSIS
- 12.1.6. KEY STRATEGIES
12.2. GILEAD SCIENCES, INC.
- 12.2.1. COMPANY OVERVIEW
- 12.2.2. FINANCIAL OVERVIEW
- 12.2.3. PRODUCTS OFFERED
- 12.2.4. KEY DEVELOPMENTS
- 12.2.5. SWOT ANALYSIS
- 12.2.6. KEY STRATEGIES
12.3. CELLERON THERAPEUTICS
- 12.3.1. COMPANY OVERVIEW
- 12.3.2. FINANCIAL OVERVIEW
- 12.3.3. PRODUCTS OFFERED
- 12.3.4. KEY DEVELOPMENTS
- 12.3.5. SWOT ANALYSIS
- 12.3.6. KEY STRATEGIES
12.4. ILLUMINA, INC.
- 12.4.1. COMPANY OVERVIEW
- 12.4.2. FINANCIAL OVERVIEW
- 12.4.3. PRODUCTS OFFERED
- 12.4.4. KEY DEVELOPMENTS
- 12.4.5. SWOT ANALYSIS
- 12.4.6. KEY STRATEGIES
12.5. ASTRAZENECA PLC
- 12.5.1. COMPANY OVERVIEW
- 12.5.2. FINANCIAL OVERVIEW
- 12.5.3. PRODUCTS OFFERED
- 12.5.4. KEY DEVELOPMENTS
- 12.5.5. SWOT ANALYSIS
- 12.5.6. KEY STRATEGIES
12.6. LISEN LMPRINTING DIAGNOSTICS
- 12.6.1. COMPANY OVERVIEW
- 12.6.2. FINANCIAL OVERVIEW
- 12.6.3. PRODUCTS OFFERED
- 12.6.4. KEY DEVELOPMENTS
- 12.6.5. SWOT ANALYSIS
- 12.6.6. KEY STRATEGIES
12.7. SALARIUS PHARMACEUTICALS, INC.
- 12.7.1. COMPANY OVERVIEW
- 12.7.2. FINANCIAL OVERVIEW
- 12.7.3. PRODUCTS OFFERED
- 12.7.4. KEY DEVELOPMENTS
- 12.7.5. SWOT ANALYSIS
- 12.7.6. KEY STRATEGIES
12.8. JUBILANT THERAPEUTICS
- 12.8.1. COMPANY OVERVIEW
- 12.8.2. FINANCIAL OVERVIEW
- 12.8.3. PRODUCTS OFFERED
- 12.8.4. KEY DEVELOPMENTS
- 12.8.5. SWOT ANALYSIS
- 12.8.6. KEY STRATEGIES
12.9. ORYZON GENOMICS
- 12.9.1. COMPANY OVERVIEW
- 12.9.2. FINANCIAL OVERVIEW
- 12.9.3. PRODUCTS OFFERED
- 12.9.4. KEY DEVELOPMENTS
- 12.9.5. SWOT ANALYSIS
- 12.9.6. KEY STRATEGIES
12.10. EPIAXIS THERAPEUTICS
- 12.10.1. COMPANY OVERVIEW
- 12.10.2. FINANCIAL OVERVIEW
- 12.10.3. PRODUCTS OFFERED
- 12.10.4. KEY DEVELOPMENTS
- 12.10.5. SWOT ANALYSIS
- 12.10.6. KEY STRATEGIES

13. APPENDIX

13.1. REFERENCES
13.2. RELATED REPORTS